{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma+of+Head%2FNeck&page=60",
    "query": {
      "condition": "Carcinoma of Head/Neck",
      "page": 60
    },
    "page_size": 10
  },
  "pagination": {
    "page": 60,
    "page_size": 10,
    "total_count": 1997,
    "total_pages": 200,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma+of+Head%2FNeck&page=61&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma+of+Head%2FNeck&page=59&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-28T20:52:58.745Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04272034",
      "title": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "MSI-H/dMMR Tumors",
        "Cutaneous Squamous Cell Carcinoma",
        "Urothelial Carcinoma, HCC",
        "Cervical Cancer",
        "Esophageal Squamous Cell Carcinoma",
        "Merkel Cell Carcinoma",
        "Small-cell Lung Cancer",
        "Mesothelioma",
        "PD-L1 Amplified Tumor (9p24.1)",
        "Nasopharyngeal Carcinoma",
        "Cyclin-dependent Kinase 12 Mutated Tumors",
        "Basal Cell Carcinoma (Unresectable or Metastatic)",
        "Sarcomatoid Renal Cell Carcinoma",
        "Clear Cell Ovarian or Endometrial Carcinoma",
        "Anal Carcinoma",
        "Squamous Cell Penile Carcinoma",
        "DNA Polymerase Epsilon Mutated Tumors (P286R and V411L)"
      ],
      "interventions": [
        {
          "name": "INCB099318",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 105,
      "start_date": "2021-03-26",
      "completion_date": "2024-08-16",
      "has_results": false,
      "last_update_posted_date": "2025-10-16",
      "last_synced_at": "2026-10-28T20:52:58.745Z",
      "location_count": 3,
      "location_summary": "Hackensack, New Jersey • Greenville, South Carolina • Nashville, Tennessee",
      "locations": [
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "Greenville",
          "state": "South Carolina"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04272034"
    },
    {
      "nct_id": "NCT02812524",
      "title": "Ipilimumab for Head and Neck Cancer Patients",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Squamous Cell Carcinoma of the Head and Neck"
      ],
      "interventions": [
        {
          "name": "Intratumoral Ipilimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Providence Health & Services",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2016-11-18",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-04-24",
      "last_synced_at": "2026-10-28T20:52:58.745Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02812524"
    },
    {
      "nct_id": "NCT02526017",
      "title": "Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "Head and Neck Cancer",
        "Pancreatic Cancer",
        "Ovarian Cancer",
        "Renal Cell Carcinoma",
        "Malignant Glioma",
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Cabiralizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Five Prime Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 313,
      "start_date": "2015-09-08",
      "completion_date": "2019-11-18",
      "has_results": true,
      "last_update_posted_date": "2022-03-09",
      "last_synced_at": "2026-10-28T20:52:58.745Z",
      "location_count": 39,
      "location_summary": "Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 27 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02526017"
    },
    {
      "nct_id": "NCT03057613",
      "title": "The Addition of Pembrolizumab to Postoperative Radiotherapy in Cutaneous Squamous Cell Cancer of the Head and Neck",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Squamous Cell Carcinoma of the Head and Neck"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "IMRT 60-66Gy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2017-05-10",
      "completion_date": "2020-09-09",
      "has_results": true,
      "last_update_posted_date": "2022-06-30",
      "last_synced_at": "2026-10-28T20:52:58.745Z",
      "location_count": 2,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03057613"
    },
    {
      "nct_id": "NCT04585750",
      "title": "The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Advanced Malignant Neoplasm",
        "Metastatic Cancer",
        "Metastatic Solid Tumor",
        "Lung Cancer",
        "Ovarian Cancer",
        "Endometrial Cancer",
        "Prostate Cancer",
        "Colorectal Cancer",
        "Breast Cancer",
        "Other Cancer",
        "Locally Advanced",
        "Head and Neck Cancer",
        "Gall Bladder Cancer",
        "Small Cell Lung Cancer",
        "Small Cell Lung Cancer ( SCLC )",
        "Small Cell Lung Carcinoma",
        "NSCLC",
        "NSCLC (Non-small Cell Lung Cancer)",
        "SCLC",
        "Non-Small Cell Lung Carcinoma",
        "Triple Negative Breast Cancer",
        "TNBC",
        "HER2+ Breast Cancer",
        "Non-Small Cell Lung Cancer",
        "ER/PR Positive Breast Cancer",
        "HER2- Breast Cancer",
        "HER2-positive Breast Cancer",
        "HER2-negative Breast Cancer",
        "ER/PR(+), Her2(-) Breast Cancer"
      ],
      "interventions": [
        {
          "name": "rezatapopt",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PMV Pharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 300,
      "start_date": "2020-10-29",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-02",
      "last_synced_at": "2026-10-28T20:52:58.745Z",
      "location_count": 32,
      "location_summary": "Irvine, California • La Jolla, California • Los Angeles, California + 26 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04585750"
    },
    {
      "nct_id": "NCT03997643",
      "title": "Preservation of Swallowing in Respected Oral Cavity Squamous Cell Carcinoma: Examining Radiation Volume Effects (PRESERVE): A Randomized Trial",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "Radiotherapy to all dissected areas",
          "type": "RADIATION"
        },
        {
          "name": "Omit radiation to pN0 neck",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 90,
      "start_date": "2019-09-06",
      "completion_date": "2027-09",
      "has_results": false,
      "last_update_posted_date": "2026-10-05",
      "last_synced_at": "2026-10-28T20:52:58.745Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03997643"
    },
    {
      "nct_id": "NCT05526924",
      "title": "Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Head and Neck Cancer",
        "Head and Neck Squamous Cell Carcinoma",
        "Head and Neck Carcinoma",
        "Head and Neck Cancer Stage IV",
        "Head and Neck Cancers - Throat"
      ],
      "interventions": [
        {
          "name": "Chemoradiation",
          "type": "RADIATION"
        },
        {
          "name": "Pamiparib",
          "type": "DRUG"
        },
        {
          "name": "Hydroxyurea",
          "type": "DRUG"
        },
        {
          "name": "Fluorouracil (5FU)",
          "type": "DRUG"
        },
        {
          "name": "Tislelizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2023-03-07",
      "completion_date": "2028-01-01",
      "has_results": false,
      "last_update_posted_date": "2026-03-04",
      "last_synced_at": "2026-10-28T20:52:58.745Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05526924"
    },
    {
      "nct_id": "NCT07090499",
      "title": "A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced/Metastatic Solid Tumors",
        "Bladder Cancer",
        "Urothelial Carcinoma",
        "Advanced Non-Small Cell Lung Cancer",
        "Carcinoma, Non Small Cell Lung",
        "Carcinoma, Squamous Cell of Head and Neck",
        "Head and Neck Cancer",
        "Esophageal Cancer",
        "Gastroesophageal Junction Adenocarcinoma",
        "Esophageal Squamous Cell Carcinoma",
        "Esophageal Adenocarcinoma",
        "Pancreatic Adenocarcinoma",
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "PF-08046876",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Cisplatin",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Carboplatin",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 540,
      "start_date": "2025-08-20",
      "completion_date": "2029-07-08",
      "has_results": false,
      "last_update_posted_date": "2026-10-13",
      "last_synced_at": "2026-10-28T20:52:58.745Z",
      "location_count": 21,
      "location_summary": "Duarte, California • Irvine, California • Los Angeles, California + 11 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07090499"
    },
    {
      "nct_id": "NCT00006471",
      "title": "Fenretinide in Treating Patients With Recurrent or Metastatic Head and Neck Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "Fenretinide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2000-09",
      "completion_date": "2004-07",
      "has_results": false,
      "last_update_posted_date": "2018-11-01",
      "last_synced_at": "2026-10-28T20:52:58.745Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00006471"
    },
    {
      "nct_id": "NCT04348916",
      "title": "Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer",
        "Melanoma",
        "Solid Tumor",
        "Squamous Cell Carcinoma of Head and Neck",
        "Breast Cancer",
        "Advanced Solid Tumor",
        "Triple Negative Breast Cancer",
        "Colorectal Carcinoma",
        "Non-melanoma Skin Cancer",
        "Liver Metastases"
      ],
      "interventions": [
        {
          "name": "ONCR-177",
          "type": "BIOLOGICAL"
        },
        {
          "name": "pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Oncorus, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 66,
      "start_date": "2020-05-20",
      "completion_date": "2023-05-31",
      "has_results": false,
      "last_update_posted_date": "2023-06-08",
      "last_synced_at": "2026-10-28T20:52:58.745Z",
      "location_count": 10,
      "location_summary": "Duarte, California • Denver, Colorado • Tampa, Florida + 6 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04348916"
    }
  ]
}